Histological Subtypes Drive Distinct Prognostic Immune Signatures in Classical Hodgkin Lymphoma.

Fiche publication

Date publication

octobre 2022

Journal

Cancers

Auteurs

Membres identifiés du Cancéropôle Est :
Dr ROSSI Cédric

Tous les auteurs :
Lamaison C, Ferrant J, Gravelle P, Traverse-Glehen A, Ghesquières H, Tosolini M, Rossi C, Ysebaert L, Brousset P, Laurent C, Syrykh C

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/36230815

Résumé

Despite the success of standard front-line chemotherapy, 20% of classical Hodgkin lymphoma (cHL) patients still relapse or have refractory disease (r/r), and a subset of them die due to disease progression. There is a critical lack of predictive factors for early identification of those r/r patients who may benefit from new therapeutic strategies. This study aimed to evaluate the dynamic expression of 586 immune-related genes in a cohort of 42 cHL patients including 30 r/r cHL after first-line chemotherapy. Gene expression profiling (GEP) using NanoString technology identified a 19-gene immune signature at diagnosis predictive of cHL relapse, but dependent on histological subtypes. Genes related to tumor survival were found upregulated while genes related to B-lineage were downregulated at diagnosis in r/r nodular sclerosis cHL. In contrast to the mixed-cellularity subtype, comparative GEP analyses between paired diagnosis/relapse biopsies of nodular sclerosis cHL showed 118 differentially expressed genes, supporting an immune contexture switch at relapse with upregulation of immunosuppressive cytokines, such as and , and downregulation of the T-cell co-stimulatory receptor . These results indicate that the predictive value of immune signature in cHL is strongly influenced by histological subtype which should be considered when assessing new immunotherapy target strategies.